Serum adiponectin in chronic hepatitis C and B

Authors:

Abstract
Summary. Adiponectin possesses anti‐inflammatory, insulin‐sensitizing and anti‐atherosclerotic properties. The aim of this study was to assess the levels of serum adiponectin in patients with chronic viral hepatitis C and B and correlate them with parameters exploring insulin resistance and indices of chronic liver disease. Seventy‐two patients with chronic hepatitis C virus (HCV) infection and 73 patients with chronic hepatitis B virus (HBV) infection, matched for age and sex, were studied. All individuals were examined for serum concentrations of adiponectin, insulin, C‐peptide and homeostasis model assessment for insulin resistance (HOMA‐IR). Viral parameters and liver histology were also evaluated. Serum adiponectin levels were significantly higher in HCV compared with HBV‐infected patients. Correlation analysis in the whole group demonstrated that serum adiponectin was positively correlated with aspartate aminotransferase, alkaline phosphatase, globulins, high‐density lipoprotein cholesterol and staging score, while it was negatively correlated with body mass index, insulin, C‐peptide and HOMA‐IR. Logistic regression analysis identified type of infection (HCVvsHBV), alcohol consumption more than 25 g daily, serum total globulin and low C‐peptide as significant predictive variables associated with high adiponectin levels. Higher levels of serum adiponectin in HCV compared with HBV patients could have a role in the slower disease progression of chronic HCV infection. In addition, alcohol intake more than 25 g daily seems to be a significant predictor for hyperadiponectinaemia in patients with chronic viral hepatitis C or B. Finally, in this study, a clear positive association between adiponectin and hepatic necroinflammation or staging score was not found.

This publication has 31 references indexed in Scilit: